RxDoctor Payments Data

David Dodson, MD

Internal Medicine · Santa Barbara, CANPI 1619943834

Payments from drug & device makers

$1,559in general payments, 2019–2025

Across 58 payments — averaging $26.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$242
  • Pfizer$211
  • Amgen$197
  • Edwards Lifesciences$179
  • AbbVie$172
  • Silk Road Medical, Inc.$164
  • plus $395 from 8 others

What the payments were for

  • Food & beverage$1,559100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,559 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$172,647
Medicare patients
478
Services billed
1,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide116$115,471
EliquisApixaban88$84,614
JardianceEmpagliflozin52$71,983
OzempicSemaglutide67$67,721
XareltoRivaroxaban63$53,477
FarxigaDapagliflozin Propanediol35$28,845
SynjardyEmpagliflozin/Metformin Hcl21$20,156
JanumetSitagliptin Phos/Metformin Hcl11$14,307
TrulicityDulaglutide15$14,041
RybelsusSemaglutide11$11,917
MyrbetriqMirabegron11$11,873
Xigduo XrDapaglifloz Propaned/Metformin12$10,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,212
LinzessLinaclotide13$7,585
Rosuvastatin Calcium359$7,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$19$92,13973 claims
PfizerEliquis$211$84,61488 claims
Johnson & JohnsonXarelto$242$53,47763 claims
AstraZenecaFarxiga$24$28,84535 claims
MerckJanumet$125$14,30711 claims
AbbVieLinzess$172$7,58513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →